Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04203056 · ClinicalTrials.gov registry record · Phase 4
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
A Phase 4 study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT04203056 is a Phase 4 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 15 participants.
The verdict
NCT04203056, a Phase 4 study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.
Interventions
- DRUG Aripiprazole Lauroxil
- DRUG ARI-ORAL
- DRUG AL-NCD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-12-16 |
| Est. Completion | 2022-10-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04203056
The ClinicalTrials.gov registry entry for NCT04203056 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Aripiprazole Lauroxil is the first listed.
NCT04203056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04203056 about?
NCT04203056 is a clinical study titled "Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode". This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.
What is the current status of trial NCT04203056?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2019-12-16. Estimated completion is 2022-10-01.
What interventions are being tested in trial NCT04203056?
The interventions under investigation include: Aripiprazole Lauroxil (DRUG), ARI-ORAL (DRUG), AL-NCD (DRUG).
Who is sponsoring clinical trial NCT04203056?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.